Novo Nordisk (NVO) announced that the U.S. Food and Drug Administration (FDA) has approved its Alhemo (concizumab-mtci) bleeding prevention injection for patients with rare clotting disorders ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback